PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues

The combination of PARP and androgen receptor signalling inhibitors is best reserved for cases for which we expect an overall survival benefit on the basis of disease biology. The data to date should encourage us to perform more, not less, testing for DNA repair defects.

Saved in:
Bibliographic Details
Published in:European urology 2023-09, Vol.84 (3), p.253-256
Main Authors: Beije, Nick, Abida, Wassim, Antonarakis, Emmanuel S., Castro, Elena, de Wit, Ronald, Fizazi, Karim, Gillessen, Silke, Hussain, Maha, Mateo, Joaquin, Morris, Michael J., Olmos, David, Sartor, Oliver, Sharp, Adam, Sweeney, Christopher J., de Bono, Johann S.
Format: Article
Language:English
Subjects:
Androgen receptor signalling inhibitor
Castration-resistant prostate cancer
DNA Repair
Humans
Male
Metastatic prostate cancer
PARP inhibitor
Poly(ADP-ribose) Polymerase Inhibitors - pharmacology
Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - genetics
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The combination of PARP and androgen receptor signalling inhibitors is best reserved for cases for which we expect an overall survival benefit on the basis of disease biology. The data to date should encourage us to perform more, not less, testing for DNA repair defects.
ISSN:0302-2838
1873-7560
1873-7560
DOI:10.1016/j.eururo.2023.03.038